Autolus Therapeutics (AUTL) Share-based Compensation (2021 - 2025)

Autolus Therapeutics (AUTL) has 5 years of Share-based Compensation data on file, last reported at $3.4 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation fell 44.76% year-over-year to $3.4 million; the trailing twelve-month figure through Dec 2025 stood at $14.4 million (down 6.68% YoY), and the FY2025 full-year result was $14.4 million, down 6.68% from the prior year.
• Share-based Compensation for Q4 2025 stood at $3.4 million, down from $3.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $7.8 million in Q4 2021 and bottomed at -$8.6 million in Q4 2022.
• The 5-year median for Share-based Compensation is $2.9 million (2022), against an average of $2.5 million.
• Peak annual rise in Share-based Compensation reached 449.25% in 2022, while the deepest fall reached 210.87% in 2022.
• A 5-year view of Share-based Compensation shows it stood at $7.8 million in 2021, then tumbled by 210.87% to -$8.6 million in 2022, then jumped by 138.09% to $3.3 million in 2023, then jumped by 90.32% to $6.2 million in 2024, then plunged by 44.76% to $3.4 million in 2025.
• The last three Share-based Compensation figures came in at $3.4 million (Q4 2025), $3.8 million (Q3 2025), and $4.3 million (Q2 2025), per Business Quant data.

Peer Comparison